Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Opinion on Biological Therapy

• Publication date

  2015-09-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14712598.2015.1071348PMID 26360115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

  2015cited by this paper
• Translational Implications of Tumor Heterogeneity

  2015cited by this paper
• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

  2015cited by this paper
• The Role of Immunohistochemical Analysis in the Evaluation of EML4-ALK Gene Rearrangement in Lung Cancer

  2015cited by this paper
• Circulating tumor DNA as a liquid biopsy for cancer.

  2015cited by this paper
• Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.

  2015cited by this paper
• Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

  2015cited by this paper
• High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

  2015cited by this paper
• The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Brain Entropy Mapping Using fMRI

  2014cited by this paper
• The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

  2014cited by this paper
• Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.

  2014cited by this paper
• Prognostic Value of MET Gene Copy Number and Protein Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Published Literatures

  2014cited by this paper
• Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

  2014cited by this paper
• T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.

  2014cited by this paper
• Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC

  2014influential reference
• Prognostic Value of Epidermal Growth Factor Receptor Mutations in Resected Non-Small Cell Lung Cancer: A Systematic Review with Meta-Analysis

  2014cited by this paper
• Circulating Tumor DNA Is Effective for the Detection of EGFR Mutation in Non–Small Cell Lung Cancer: A Meta-analysis

  2014cited by this paper
• Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.

  2014cited by this paper
• Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

  2014cited by this paper
• Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.

  2014cited by this paper
• First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.

  2014cited by this paper
• Liquid biopsies: genotyping circulating tumor DNA.

  2014cited by this paper
• Liquid biopsies in lung cancer: the new ambrosia of researchers.

  2014cited by this paper
• Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.

  2014cited by this paper
• Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis

  2014cited by this paper
• BRAF Mutations in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

  2014cited by this paper
• MET Gene Copy Number Predicts Worse Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC); A Systematic Review and Meta-Analysis

  2014cited by this paper
• Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?

  2014cited by this paper
• The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

  2014cited by this paper
• ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.

  2014cited by this paper
• The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target?

  2014cited by this paper
• Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.

  2014cited by this paper
• Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?

  2014cited by this paper
• Crizotinib in ROS1-rearranged non-small-cell lung cancer.

  2014influential reference
• Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.

  2014cited by this paper
• Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

  2014cited by this paper
• Use of statins and the risk of death in patients with prostate cancer.

  2014cited by this paper
• Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.

  2014cited by this paper
• Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

  2014cited by this paper
• Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial.

  2014influential reference
• Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).

  2014cited by this paper
• First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).

  2014cited by this paper
• Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs).

  2014cited by this paper
• Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

  2014cited by this paper
• Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.

  2014cited by this paper
• Reply to A. Soultati et Al.

  2014cited by this paper
• Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.

  2013cited by this paper
• Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.

  2013cited by this paper
• Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients

  2013cited by this paper
• The angiotensinogen gene M235T polymorphism and acute myocardial infarction risk: a meta-analysis of 22 studies

  2013cited by this paper
• Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma.

  2013cited by this paper
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013cited by this paper
• Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.

  2013cited by this paper
• ROS1-Rearranged Lung Cancer: A Clinicopathologic and Molecular Study of 15 Surgical Cases

  2013cited by this paper
• Immunohistochemical Profiling of ALK Fusion Gene–Positive Adenocarcinomas of the Lung

  2013cited by this paper
• Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas

  2013cited by this paper
• High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?

  2013cited by this paper
• Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

  2013cited by this paper
• Molecular Pathways Molecular Pathways : ROS 1 Fusion Proteins in Cancer

  2013cited by this paper
• Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization

  2013cited by this paper
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

  2013cited by this paper
• Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.

  2013cited by this paper
• Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

  2013cited by this paper
• Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.

  2013cited by this paper
• Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib.

  2013cited by this paper
• Monitoring response to therapy in patients with cancer: is circulating DNA the answer?

  2013cited by this paper
• Identification of somatic genomic alterations in circulating tumors cells: another step forward in non-small-cell lung cancer?

  2013cited by this paper
• Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer

  2013cited by this paper
• Prognostic Significance of Circulating Tumor Cells in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis

  2013cited by this paper
• KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts).

  2012cited by this paper
• ROS1 rearrangements define a unique molecular class of lung cancers.

  2012cited by this paper
• Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.

  2012cited by this paper
• ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

  2012cited by this paper
• Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

  2012cited by this paper
• linical activity of afatinib ( BIBW 2992 ) in patients with lung adenocarcinoma ith mutations in the kinase domain of HER 2 / neu

  2012cited by this paper
• RET, ROS1 and ALK fusions in lung cancer

  2012cited by this paper
• Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains

  2012cited by this paper
• First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

  2012cited by this paper
• Circulating tumor-derived biomarkers in lung cancer.

  2012cited by this paper
• Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).

  2012cited by this paper
• Concomitant Actionable Mutations and Overall Survival (OS) in Egfr-Mutant Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Included in The Eurtac Trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3)

  2012cited by this paper
• Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

  2012cited by this paper
• Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation

  2012cited by this paper
• Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

  2012cited by this paper
• The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies

  2012cited by this paper
• Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

  2012cited by this paper
• Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.

  2012cited by this paper
• Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC)

  2012cited by this paper
• Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

  2012influential reference
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

  2012cited by this paper
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011cited by this paper
• EGFR genomic alterations in cancer: prognostic and predictive values.

  2011cited by this paper
• Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH

  2011cited by this paper
• Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

  2011cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

  2011influential reference

• Neuromedin U contributes to radiation resistance in colorectal cancer via YAP/TAZ signaling activation.

  2023cites this paper
• Potential agnostic role of BRCA alterations in patients with several solid tumors: one for all, all for one?

  2023cites this paper
• Lung Cancer Recurrence Risk Prediction through Integrated Deep Learning Evaluation

  2022cites this paper
• Lung Cancer

  2021cites this paper
• Tumor Biology and Natural History

  2021cites this paper
• Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics

  2020cites this paper
• COPD_A_271864 2727..2737

  2020cites this paper
• Circulating miR-1246 in the Progression of Chronic Obstructive Pulmonary Disease (COPD) in Patients from the BODE Cohort

  2020cites this paper
• The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress

  2018cites this paper
• Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes

  2018cites this paper
• Tumor-associated metabolic and inflammatory responses in early stage non-small cell lung cancer: Local patterns and prognostic significance.

  2018cites this paper
• Magnolol Inhibits the Growth of Non-Small Cell Lung Cancer via Inhibiting Microtubule Polymerization

  2017cites this paper
• Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review

  2017cites this paper
• Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer

  2017cites this paper
• Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence

  2017cites this paper
• EGFR inhibition in NSCLC: New findings…. and opened questions?

  2017cites this paper
• Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC)

  2017cites this paper
• KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients.

  2016influential citation
• Adding chemotherapy to TKI: can we improve first-line treatment for EGFR-mutated NSCLC patients?

  2016cites this paper
• PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

  2016cites this paper
• Nintedanib in NSCLC: evidence to date and place in therapy

  2016cites this paper
• Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer.

  2016cites this paper
• The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer

  2016cites this paper
• Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway

  2016cites this paper
• An integrative strategy for targeted evaluation of biomarker expression in non-small cell lung cancer

  2016cites this paper
• The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status

  2016cites this paper
• Overcoming Resistance to EGFR-Tkis: The Potential Role of Third-Generation Inhibitors

  2016cites this paper
• The concept of entropy in histopathological diagnosis and targeted therapy

  2015cites this paper